OOIR: Observatory of International Research

Papers

(The median citation count of Seminars in Hematology is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Memory-like natural killer cells for cancer immunotherapy	48
Iron metabolism in infections: Focus on COVID-19	47
Toward a pathophysiology inspired treatment of VEXAS syndrome	39
Treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT)	31
Epidemiology of VITT	30
Aplastic anemia: Pathophysiology	30
Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT)	28
Characteristic bone marrow findings in patients with UBA1 somatic mutations and VEXAS syndrome	26
Platelet-activating anti-PF4 disorders: An overview	26
Mechanisms of cellular iron sensing, regulation of erythropoiesis and mitochondrial iron utilization	24
Thrombotic manifestations of VEXAS syndrome	24
Genetics of somatic auto-inflammatory disorders	22
VEXAS within the spectrum of rheumatologic disease	22
Clonal hematopoiesis and VEXAS syndrome: survival of the fittest clones?	22
Improving CAR T cell therapy by optimizing critical quality attributes	22
Modulating NK cell metabolism for cancer immunotherapy	20
Monitoring MRD in ALL: Methodologies, technical aspects and optimal time points for measurement	19
Genetic and epigenetic modification of human primary NK cells for enhanced antitumor activity	16
20 years of Hepcidin: How far we have come	16
Recent advances in use of fresh frozen plasma, cryoprecipitate, immunoglobulins, and clotting factors for transfusion support in patients with hematologic disease	15
Platelet transfusion: Alloimmunization and refractoriness	13
Improving CAR T-cells: The next generation	13
VEXAS syndrome: An inflammatory and hematologic disease	13
Shaping the bone through iron and iron-related proteins	12
Laboratory testing for VITT antibodies	11

Natural killer cell engineering – a new hope for cancer immunotherapy	11
Role of blinatumomab, inotuzumab, and CAR T-cells: Which to choose and how to sequence for patients with relapsed disease	11
NK cells as adoptive cellular therapy for hematological malignancies: Advantages and hurdles	10
Longitudinal Aspects of VITT	10
Immunosuppressive therapy in severe aplastic anemia	9
TET-dioxygenase deficiency in oncogenesis and its targeting for tumor-selective therapeutics	9
Looking beyond VEXAS: Coexistence of undifferentiated systemic autoinflammatory disease and myelodysplastic syndrome	9
Applications of virus-specific T cell therapies post-BMT	9
Pharmacogenomics and ALL treatment: How to optimize therapy	9
Transfusion support in patients with sickle cell disease	8
DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multipl	8
Selection of allogeneic hematopoietic cell transplant donors to optimize natural killer cell alloreactivity	8
Clonality in immune aplastic anemia: Mechanisms of immune escape or malignant transformation	8
The spectrum of somatic mutations in large granular lymphocyte leukemia, rheumatoid arthritis, and Felty's syndrome	7
Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria	7
Philadelphia chromosome positive acute lymphoblastic leukemia in adults: Therapeutic options and dilemmas in 2020	7
The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia	7
A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies	7
Optimal approach to the treatment of young adults with acute lymphoblastic leukemia in 2020	6
Diagnosis and management of adult T-cell leukemia/lymphoma	6
The challenge to further improvements in survival of patients with T-ALL: Current treatments and new insights from disease pathogenesis	5
Advances in understanding the crosstalk between mother and fetus on iron utilization	5
Iron and erythropoiesis: A mutual alliance	5
Hemolytic paroxysmal nocturnal hemoglobinuria: 20 years of medical progress	5
Place of care manufacturing of chimeric antigen receptor cells: Opportunities and challenges	5
SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies	5
Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients	5
Aplastic anemia: Quo vadis?	4
Clinical picture of VITT	4
Somatic mutations in VEXAS Syndrome and Erdheim-Chester disease: Inflammatory myeloid diseases	4
The role of viruses in HIV-associated lymphomas	4
Advances in gene therapy for hematologic disease and considerations for transfusion medicine	4
Gene editing for sickle cell disease and transfusion dependent thalassemias- A cure within reach	4
Vaccine-induced immune thrombotic thrombocytopenia (VITT)	4
Epigenetic modifier directed therapeutics to unleash healthy genes in unhealthy cells	4
The epidemiology of Waldenström macroglobulinemia	4
Novel therapies targeting cutaneous T cell lymphomas and their microenvironment	4
Management of Angioimmunoblastic T-Cell Lymphoma (AITL) and other T Follicular Helper Cell lymphomas (TFH PTCL)	4
Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin	4
Extranodal natural killer/T-cell lymphoma: An overview on pathology and clinical management	4
Epigenetic activities in erythroid cell gene regulation	4
Somatic mutations in acquired pure red cell aplasia	4
Somatic mutations and clonal expansions in paroxysmal nocturnal hemoglobinuria	4
Cell senescence and malignant transformation in the inherited bone marrow failure syndromes: Overlapping pathophysiology with therapeutic implications	4
Mendelian inheritance of anemia due to disturbed iron homeostasis	3
Somatic compensation of inherited bone marrow failure	3
Clonal dynamics of hematopoietic stem cell compartment in aplastic anemia	3
The evolution of NK cell immunotherapy for hematologic malignancies: A historical and contemporary perspective	3
Challenges and opportunities of CAR T-cell therapies for CLL	3
Hepatitis C virus-associated B-cell lymphomas: The importance of the new direct antiviral agent therapy	3

Prognosis and risk stratification of peripheral T-cell lymphomas	3
New approaches to the treatment of older adults with acute lymphoblastic leukemia	3
Transfusion support for stem cell transplant recipients	3
Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia	3
Clinical manifestations of clonal hematopoiesis: What has SF3B1-mutant MDS taught us?	3
Primary and secondary central nervous system mature T- and NK-cell lymphomas	3
Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management	3
Infectious complications of chimeric antigen receptor (CAR) T-cell therapies	2
Palliative care needs of patients with hematologic malignancies and family caregivers and challenges of palliative care provision in Asia: A review of evidence	2
Transfusion support: Considerations in pediatric populations	2
Access to essential therapy for sickle cell disease in Africa: Experience from a national program in Ghana	2
The psychiatric and psychological sequelae of vaccine-induced immune thrombotic thrombocytopenia (VITT)	2
DLBCL arising from indolent lymphomas: How are they different?	2
The natural killer cell immunotherapy platform: An overview of the landscape of clinical trials in liquid and solid tumors	2
Epidemiology and etiology of diffuse large B-cell lymphoma	2
Molecularly targeted therapies for relapsed and refractory peripheral T-cell lymphomas	2
Highlights of the 11th International Workshop on Waldenstrom's Macroglobulinemia: What we learned, and how it will impact scientific discovery and patient care	2
Clinical applications of circulating tumor DNA in central nervous system lymphoma	2
Current challenges and new approaches to implementing optimal management of sickle cell disease in sub-Saharan Africa	2